Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
BAY 58-2667 . hydrochloride
90
CHF
CHF 90.00
In stock
AG-CR1-3509-M0011 mgCHF 90.00
| Product Details | |
|---|---|
| Synonyms | Cinaciguat . hydrochloride |
| Product Type | Chemical |
| Properties | |
| Formula |
C36H39NO5 . HCl . 0.5H2O |
| MW | 565.6 . 36.5 . 9.0 |
| CAS | 646995-35-9 |
| Purity Chemicals | ≥98% (NMR) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO. |
| Identity | Determined by 1H-NMR. |
| InChi Key | LLHMBJOVHATVSP-UHFFFAOYSA-N |
| Smiles | Cl.OC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC1=CC=C(C=C1)C(O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator.
- Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
- Exhibits potent vasodilator and antiplatelet activity.
- Anti-aggregating agent.
Product References
- NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle: J.P. Stasch, et al.; Br. J. Pharmacol. 136, 773 (2002)
- Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase: P. Schmidt, et al.; Eur. J. Pharmacol. 468, 167 (2003)
- Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease: G. Boerrigter & JC. Burnett Jr.; Cardiovasc. Drug Rev. 25, 30 (2007) (Review)
- Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers: R. Frey, et al.; J. Clin. Pharmacol. 48, 1400 (2008)
- BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts: T. Krieg, et al.; Eur. Heart J. 30, 1607 (2009)
- Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure: H. Lapp, et al.; Circulation 119, 2781 (2009)
- Role of guanylate cyclase modulators in decompensated heart failure: V. Mitrovic, et al.; Heart Fail. Rev. 14, 309 (2009) (Review)
- Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure: J. Tamargo, et al.; Curr. Opin. Investig. Drugs 11, 1039 (2010)
- Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase: S. Roger, et al.; Vascul. Pharmacol. 53, 281 (2010)
- Transgenic mice for real time visualization of cGMP in intact adult cardiomyocytes: K. Götz, et al.; Circ. Res. 114, 1235 (2014)
- Soluble Guanylate Cyclase as a Novel Treatment Target for Osteoporosis: J. Joshua, et al., Endocrinology 155, 4720 (2014)
- Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice: M.G. de Oliveira, et al.; Am. J. Physiol. Renal Physiol. 311, F85 (2016)
Related Products
